What You Should Know:
– Philips announced the launch of the Philips ECG AI Marketplace, a new platform that provides cardiac care teams with a central location to access multiple vendor offerings, simplifying the management and implementation of AI-powered diagnostic tools.
– Anumana, an AI-driven health technology company focused on transforming cardiac care, is the first organization to leverage this platform, with its FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm now available in the Marketplace.
– As clinicians increasingly adopt AI-powered tools, healthcare organizations are working with various platforms and solutions. The Philips ECG AI Marketplace enables U.S. hospitals and health systems to seamlessly integrate validated algorithms into their existing Philips infrastructure and workflows.
Streamlining AI Integration and Accelerating Diagnostics
The Philips ECG AI Marketplace aims to significantly improve operational costs and efficiency for hospitals by centralizing the management of vendor connections for each AI solution, thereby removing the need for dedicated IT resources to oversee multiple interfaces. This direct access to a broad portfolio of AI tools at the point of care also helps reduce the time clinicians spend reviewing ECG results and fast-tracks diagnoses for patients.
Anumana’s LEF Algorithm: A Flagship Offering
Anumana’s FDA breakthrough-designated LEF algorithm is now integrated across Philips’ ECG portfolio through the Philips ECG AI Marketplace, including IntelliSpace ECG and Philips cardiographs. The LEF algorithm analyzes a standard 12-lead resting ECG to identify reduced ejection fraction, which is an early indicator of heart failure. By making Anumana’s algorithm available through the Marketplace, healthcare providers can access AI-powered cardiac insights during routine ECG ordering and interpretation, supporting timely and informed care.
“We’re proud to be the flagship offering on the Philips ECG AI Marketplace,” said Simos Kedikoglou, MD, President and Chief Operating Officer at Anumana. “Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance. Anumana’s AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications. By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure.”
